Literature DB >> 30568989

A Strategy for PrEP Clinicians to Manage Ambiguous HIV Test Results During Follow-up Visits.

Dawn K Smith1,2, William M Switzer1,2, Philip Peters1,2, Kevin P Delaney1,2, Timothy C Granade1,2, Silvina Masciotra1,2, Luke Shouse1,2, John T Brooks1,2.   

Abstract

Prompt determination of HIV infection status is critical during follow-up visits for patients taking pre-exposure prophylaxis (PrEP) medication. Those who are uninfected can then continue safely taking PrEP, and those few who have acquired HIV infection can initiate an effective treatment regimen. However, a few recent cases have been reported of ambiguous HIV test results using common testing algorithms in PrEP patients. We review published reports of such cases and testing options that can be used to clarify true HIV status in these situations. In addition, we review the benefits and risks of 3 antiretroviral management options in these patients: (1) continue PrEP while conducting additional HIV tests, (2) initiate antiretroviral therapy for presumptive HIV infection while conducting confirmatory tests, or (3) discontinue PrEP to reassess HIV status after a brief antiretroviral-free interval. A clinical consultation resource is also provided.

Entities:  

Keywords:  HIV testing; PrEP; pre-exposure prophylaxis; seroconversion

Year:  2018        PMID: 30568989      PMCID: PMC6105113          DOI: 10.1093/ofid/ofy180

Source DB:  PubMed          Journal:  Open Forum Infect Dis        ISSN: 2328-8957            Impact factor:   3.835


  7 in total

1.  A New Perspective on HIV Diagnostics: Reinterpretation in the Age of Early Treatment.

Authors:  Sheila M Keating
Journal:  J Clin Microbiol       Date:  2019-09-24       Impact factor: 5.948

2.  HIV antiretroviral therapy and prevention use in US blood donors: a new blood safety concern.

Authors:  Brian Custer; Claire Quiner; Richard Haaland; Amy Martin; Mars Stone; Rita Reik; Whitney R Steele; Debra Kessler; Phillip C Williamson; Steven A Anderson; Alan E Williams; Henry F Raymond; Willi McFarland; William T Robinson; Sara Glick; Kwa Sey; C David Melton; Simone A Glynn; Susan L Stramer; Michael P Busch
Journal:  Blood       Date:  2020-09-10       Impact factor: 22.113

3.  Am I Positive? Improving Human Immunodeficiency Virus Testing in the Era of Preexposure Prophylaxis and Immediate Antiretroviral Therapy Using Machine Learning.

Authors:  Jason Zucker; Caroline Carnevale; Peter Gordon; Magdalena E Sobieszczyk; Alex J Rai
Journal:  Open Forum Infect Dis       Date:  2022-05-18       Impact factor: 4.423

4.  Evaluation of SAMBA II: A Qualitative and Semiquantitative HIV Point-of-Care Nucleic Acid Test.

Authors:  Lauren R Violette; Andy Cornelius-Hudson; Madison Snidarich; Lisa A Niemann; Sonny Michael Assennato; Allyson Ritchie; Neha Goel; Pollyanna R Chavez; Steven F Ethridge; David A Katz; Helen Lee; Kevin P Delaney; Joanne D Stekler
Journal:  J Acquir Immune Defic Syndr       Date:  2022-04-15       Impact factor: 3.771

5.  Challenges to the performance of current HIV diagnostic assays and the need for centralized specimen archives: a review of the Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA) repository.

Authors:  Shelley N Facente; Michael P Busch; Eduard Grebe; Christopher D Pilcher; Alex Welte; Brian Rice; Gary Murphy
Journal:  Gates Open Res       Date:  2019-07-23

Review 6.  Challenges of HIV diagnosis and management in the context of pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), test and start and acute HIV infection: a scoping review.

Authors:  Tamara Elliott; Eduard J Sanders; Meg Doherty; Thumbi Ndung'u; Myron Cohen; Pragna Patel; Gus Cairns; Sarah E Rutstein; Jintanat Ananworanich; Colin Brown; Sarah Fidler
Journal:  J Int AIDS Soc       Date:  2019-12       Impact factor: 5.396

7.  Incentives conditioned on tenofovir levels to support PrEP adherence among young South African women: a randomized trial.

Authors:  Connie L Celum; Katherine Gill; Jennifer F Morton; Gabrielle Stein; Laura Myers; Katherine K Thomas; Margaret McConnell; Ariane van der Straten; Jared M Baeten; Menna Duyver; Eve Mendel; Keshani Naidoo; Jacqui Dallimore; Lubbe Wiesner; Linda-Gail Bekker
Journal:  J Int AIDS Soc       Date:  2020-11       Impact factor: 5.396

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.